Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Oslo, Norway, 12 October 2018 Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators will present data and analyses from its non-clinical and clinical studies with Betalutin® (177Lu-lilotomab satetraxetan) at the 32nd Annual Congress of the European Association of Nuclear Medicine (13-17 October 2018, Düsseldorf, Germany). The presentations are: Therapeutic efficacy of 177Lu-lilotomab satetraxetan in non-Hodgkin B-cell Lymphoma is controlled by G2/M cell cycle progression Authors: A. Pichard et al. Session: 305 - M2M: Therapy Effects, Preclinical